RI
SABS icon

RTW Investments’s SAB Biotherapeutics SABS Stock Holding History

RTW Investments’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-635,276
Closed -$1.72M – 75
2024
Q3 		$1.72M Sell
635,276
-131,670
-17% -$365K 0.02% 64
2024
Q2 		$2.38M Sell
766,946
-150,881
-16% -$553K 0.04% 62
2024
Q1 		$4.17M Sell
917,827
-1
-0% -$6 0.06% 64
2023
Q4 		$6.31M Buy
+917,828
New +$7.7M 0.1% 57

Other funds holding SABS

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HWM
HB Wealth Management Atlanta, Georgia $15.5B AUM 18.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments's SABS Position: Q4 2024 in Review

RTW Investments sold out of SAB Biotherapeutics (SABS) in Q4 2024, closing a stake of 635,276 shares — an estimated $1.72M sold.

RTW Investments first reported a position in SABS in Q4 2023 and held it in 4 quarters. The position peaked at $6.31M in Q4 2023. 25 funds tracked by Wall St. Rank hold SABS as of Q4 2024.

  • RTW Investments reported no remaining SAB Biotherapeutics position as of Q4 2024 after selling out during the quarter.
  • RTW Investments sold 635,276 SAB Biotherapeutics shares in Q4 2024, an estimated $1.72M.
  • RTW Investments first reported a position in SAB Biotherapeutics in Q4 2023 and held it in 4 quarters.
  • RTW Investments's SAB Biotherapeutics position peaked at $6.31M in Q4 2023.
  • 25 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q4 2024.

Based on RTW Investments's 13F filing for Q4 2024, filed 14 Feb 2025.